Table 1.
Patient characteristics (n = 130)
| Age (years) | |
| Median (range) | 64 (49,81) |
| Tumour stage | |
| T2 | 40 (31%) |
| T3 | 86 (66%) |
| Tx | 4 (3%) |
| Nodal status | |
| N0 | 91 (70%) |
| N1 | 5 (4%) |
| Nx | 34 (26%) |
| Gleason score | |
| 6 | 5 (4%) |
| 7 | 81 (62%) |
| 8 | 4 (3%) |
| 9 | 35 (27%) |
| Not reported | 5 (4%) |
| Surgical margin | |
| Positive | 57 (44%) |
| Negative | 64 (49%) |
| Equivocal | 9 (7%) |
| Pre‐RT PSA | |
| ≤0.2 | 96 (74%) |
| Mean (SD) | 0.39 (±0.97) |
| RT dose (Gy) | |
| Median (range) | 65 (64,72) |
| Time from RP to RT (years) | |
| Mean (SD) | 2.64 (±2.74) |
| Technique | |
| 3DCRT | 53 (41%) |
| IMRT or VMAT | 77 (59%) |
| ADT | |
| Yes | 28 (22%) |
| No | 102 (78%) |
| Pelvic nodal irradiation | |
| Yes | 20 (15%) |
| No | 110 (85%) |
RT, radiation therapy; RP, radical prostatectomy; 3D‐CRT, 3D‐conformal radiation therapy; IMRT, intensity‐modulated radiation therapy; VMAT, volumetric modulated arc therapy; ADT, androgen deprivation therapy.